Value
2.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 4.0 |
- ▸Expensive valuation
ARWR · Why this verdict
Why Arrowhead Pharmaceuticals (ARWR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
All commercial exposure rests on a single approved product, creating a binary risk profile where any clinical setback, competitive approval, or reimbursement challenge could materially impair the entire revenue base with no other product line to provide offset. Bear case | Revenue from the primary approved product falls below 90% of total quarterly revenue for two consecutive quarters, indicating a second revenue source has reached commercial scale. | →Stable |
| CounterA single best-in-class approved product can generate substantial and growing revenue if market penetration tracks ahead of expectations; pipeline optionality provides additional upside without requiring an immediate second approval. | ||
With only 1.9% headroom to the near-term resistance target and a risk/reward that is unfavorable—where potential downside materially exceeds the remaining upside—the stock offers little margin of safety at current prices. The current setup does not favor new capital deployment. Price targets | Price retraces to a level where upside to the resistance target exceeds 10%, providing a more attractive risk/reward for new capital deployment. | →Stable |
| CounterAnalyst sentiment is broadly constructive, and the near-term technical target may lag a fundamental re-rating; a positive pipeline catalyst could render the current resistance level obsolete and drive a rapid price move. | ||
Free cash flow is negative at 7% of revenue, the Rule of 40 score is deeply negative at -94, and the Piotroski F-Score of 3 out of 9 signals broad-based financial weakness across profitability, leverage, and operating efficiency dimensions. The business is not yet self-funding, and current metrics do not support the valuation. Quality breakdown | Free cash flow turns positive on a quarterly basis within the next four quarters, and the Rule of 40 score rises above zero, indicating the business is approaching operational self-sufficiency. | →Stable |
| CounterTwo of the three most recent quarters delivered earnings beats, suggesting the loss rate is narrowing faster than expected; a licensing milestone or royalty-driven revenue step-up could dramatically improve cash generation within a single reporting period. | ||
The two most recent quarters both beat estimates—including a 160% positive surprise in one period—after two prior misses, suggesting the earnings trajectory may be improving from a low base. If this momentum continues, it could serve as an early signal of fundamental recovery. Earnings | EPS surprise remains positive for two more consecutive quarters, confirming that the earnings recovery is durable rather than a one-off statistical anomaly from low base estimates. | →Stable |
| CounterThe two prior quarters were misses, and the company remains cash-flow negative; the recent beats may reflect conservative resetting of estimates after prior disappointments rather than genuine fundamental improvement, making a reversal back to misses plausible. | ||
All commercial exposure rests on a single approved product, creating a binary risk profile where any clinical setback, competitive approval, or reimbursement challenge could materially impair the entire revenue base with no other product line to provide offset.
→StableBear case
- Expectation
- Revenue from the primary approved product falls below 90% of total quarterly revenue for two consecutive quarters, indicating a second revenue source has reached commercial scale.
CounterA single best-in-class approved product can generate substantial and growing revenue if market penetration tracks ahead of expectations; pipeline optionality provides additional upside without requiring an immediate second approval.
With only 1.9% headroom to the near-term resistance target and a risk/reward that is unfavorable—where potential downside materially exceeds the remaining upside—the stock offers little margin of safety at current prices. The current setup does not favor new capital deployment.
→StablePrice targets
- Expectation
- Price retraces to a level where upside to the resistance target exceeds 10%, providing a more attractive risk/reward for new capital deployment.
CounterAnalyst sentiment is broadly constructive, and the near-term technical target may lag a fundamental re-rating; a positive pipeline catalyst could render the current resistance level obsolete and drive a rapid price move.
Free cash flow is negative at 7% of revenue, the Rule of 40 score is deeply negative at -94, and the Piotroski F-Score of 3 out of 9 signals broad-based financial weakness across profitability, leverage, and operating efficiency dimensions. The business is not yet self-funding, and current metrics do not support the valuation.
→StableQuality breakdown
- Expectation
- Free cash flow turns positive on a quarterly basis within the next four quarters, and the Rule of 40 score rises above zero, indicating the business is approaching operational self-sufficiency.
CounterTwo of the three most recent quarters delivered earnings beats, suggesting the loss rate is narrowing faster than expected; a licensing milestone or royalty-driven revenue step-up could dramatically improve cash generation within a single reporting period.
The two most recent quarters both beat estimates—including a 160% positive surprise in one period—after two prior misses, suggesting the earnings trajectory may be improving from a low base. If this momentum continues, it could serve as an early signal of fundamental recovery.
→StableEarnings
- Expectation
- EPS surprise remains positive for two more consecutive quarters, confirming that the earnings recovery is durable rather than a one-off statistical anomaly from low base estimates.
CounterThe two prior quarters were misses, and the company remains cash-flow negative; the recent beats may reflect conservative resetting of estimates after prior disappointments rather than genuine fundamental improvement, making a reversal back to misses plausible.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Free cash flow is negative, the Rule of 40 fails at negative 94, a Piotroski F-Score of 3 out of 9 reflects broad financial weakness, and a single approved product carries all commercial risk; with only 1.9% headroom to the near-term resistance target and an unfavorable risk/reward, two recent earnings beats introduce modest optimism but do not yet support an attractive setup at current prices.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 6.8 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -7% of revenue
- ▸No competitive moat
- ▸Rule of 40: -94 (fail)
- ▸Weak Piotroski F-Score: 3/9
Growth
5.0/10data confidence 50%Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 7.1 |
| Price target | 5.9 |
- ▸LLM news sentiment: +0.70 (n=1)
Insider
7.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 9.9 |
- ▸Insider selling (low materiality) — $1,912,619 (0.016% of mkt cap)
- ▸Institutions accumulating
Peer rank
1.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 2.6 |
| growth rank | 0.7 |
Technical
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.4 |
| support resistance | 2.0 |
| 52w position | 9.2 |
| gap | 6.0 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.2 |
| days to cover | 2.4 |
| volatility | 0.5 |
| put call | 9.1 |
| implied vol | 1.9 |
| max pain risk | 5.0 |
| beta | 5.9 |
| debt equity | 2.7 |
- ▸High IV: 68%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.8>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.53
Upside
-7.9%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 68, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Insider at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.5=NEGATIVE.
The strongest dimensions are Insider at 7.5, Sentiment at 7.2, and Momentum at 6.8; the weakest are Peer rank at 1.8, Value at 2.4, and Quality at 3.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.53 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Negative Fcf Weak Fundamentals
Trip ifFree cash flow rises above $0 for 2 consecutive quarters, indicating the business achieves operational self-sufficiency.
- P2Single Product Concentration Risk
Trip ifRevenue from the primary approved product falls below 90% of total quarterly revenue for 2 consecutive quarters, confirming meaningful commercial diversification.
- P3Minimal Upside Unfavorable Setup
Trip ifPrice falls below $70, restoring more than 12% upside to the near-term resistance target and creating a constructive entry geometry.
- P4Recent Earnings Beat Improvement
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, breaking the nascent earnings recovery trend.